ArticleBMC women's health2026
Site-specific predictors of bone mineral density response to zoledronic acid in postmenopausal osteoporosis: differential roles of bone turnover markers and body mass index across skeletal sites.
Article in BMC women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPostmenopausal osteoporosis (PMOP) elevates fracture risk. Zoledronic acid effectively reduces fractures, but individual bone mineral density (BMD) responses vary. Systematic evidence on independent site-specific predictors of BMD changes across femoral neck, total hip, and lumbar spine remains scarce. This study aimed to identify independent factors associated with 12-month BMD changes at the femoral neck (ΔFNBMD), total hip (ΔTHBMD), and lumbar spine (ΔLSBMD) in PMOP patients (T-score ≤ - 2.5) following initial zoledronic acid treatment.
methodsA single-center retrospective cohort of 145 PMOP patients (BMD T-score ≤-2.5) was analyzed. Baseline BMD, bone turnover markers (β-cross-linked C-terminal telopeptide of type I collagen [β-CTX-I], N-terminal propeptide of type I procollagen [PINP]), blood biochemistry, and body mass index (BMI) were assessed. BMD was reassessed at the 12-month follow-up. Multiple regression and logistic models identified predictors of ΔFNBMD, ΔTHBMD, and ΔLSBMD. Receiver operating characteristic (ROC) analysis evaluated predictive performance.
resultsΔFNBMD correlated independently with baseline β-CTX-I (β = 0.031, P = 0.017). ΔTHBMD was associated with β-CTX-I (β = 0.036, P < 0.001) and BMI (β = 0.001, P = 0.027). ΔLSBMD linked to PINP (β = 0.000, P = 0.009), serum iron (β = 0.003, P = 0.023), and chloride (β=-0.005, P = 0.023). Logistic regression showed higher baseline PINP increased the odds of effective FNBMD improvement (odds ratio [OR] = 1.042 per 1 ng/mL increase, 95% confidence interval [CI]: 1.018-1.067, P < 0.001), while β-CTX-I (OR = 1.003, P = 0.008) and BMI (OR = 1.156, P = 0.023) influenced THBMD response. ROC analysis confirmed PINP as a robust predictor for FNBMD efficacy (area under the curve [AUC] = 0.724, P < 0.001), and β-CTX-I (AUC = 0.669, P = 0.004) and BMI (AUC = 0.637, P = 0.021) as clinically actionable predictors for THBMD efficacy.
conclusionZoledronic acid-induced BMD changes in PMOP exhibit site-specific associations with distinct biomarkers and clinical parameters. These findings provide preliminary evidence for tailoring treatment based on baseline metabolic and anthropometric profiles, though larger prospective studies are required to validate these markers for clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.